- Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model– click to read
- Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial– click to read
- Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting– click to read
Our most advanced program is focused on the treatment of hemophilia and surgical bleeding using our potent, long acting variants of proteases that promote blood clotting.
*(formerly known as CB 813d)
The Catalyst Advantage
Drug candidates for severe medical conditions
Learn more about the medicines we are developing.
Addressing diseases with unmet medical needs
Share our passion about treating disease.
We have an experienced and passionate team
Learn more about the Catalyst team and mission/culture.